Aminoglycosides & Urosepsis Survival & Renal Outcomes
- Paris, France (2025-04-12) – A recent study conducted across multiple intensive care units (ICUs) within the Assistance Publique-Hôpitaux de Paris (APHP) network investigated the effectiveness of aminoglycosides, a...
- Current guidelines suggest a combination therapy of a beta-lactam antibiotic and an aminoglycoside.
- The retrospective study analyzed data from adult patients admitted to the ICU with urosepsis or septic shock stemming from a urinary source.
Aminoglycosides’ Impact on Urosepsis Survival: ICU Study
Table of Contents
- Aminoglycosides’ Impact on Urosepsis Survival: ICU Study
- Aminoglycosides and Urosepsis Treatment: A Study of ICU Patients
- What is Urosepsis?
- Why are aminoglycosides Used in Urosepsis Treatment?
- Study Overview: Aminoglycosides and 30-day survival Rates in Urosepsis
- What Were the Study’s Main Findings?
- Did aminoglycosides Improve Survival in Urosepsis Patients?
- Were There Any Negative Kidney Effects Associated With Aminoglycosides?
- Key Outcomes Compared Between Aminoglycoside and Non-Aminoglycoside Groups
- Study Conclusion
- Keywords
Paris, France (2025-04-12) – A recent study conducted across multiple intensive care units (ICUs) within the Assistance Publique-Hôpitaux de Paris (APHP) network investigated the effectiveness of aminoglycosides, a class of antibiotics, in treating urosepsis, a severe infection originating in the urinary tract. The research, spanning from January 2015 to May 2022, focused on patient survival and kidney-related outcomes.
Background: Urosepsis Treatment and Kidney Concerns
Urosepsis, when severe, often requires immediate treatment. Current guidelines suggest a combination therapy of a beta-lactam antibiotic and an aminoglycoside. However, aminoglycosides are known to potentially cause nephrotoxicity, or kidney damage. Acute kidney injury (AKI) is a serious complication for patients in septic shock, prompting this examination into the real-world impact of aminoglycoside use in urosepsis cases.
Study Design and Methodology
The retrospective study analyzed data from adult patients admitted to the ICU with urosepsis or septic shock stemming from a urinary source. Researchers tracked several key outcomes, including mortality within 30 days of ICU admission. Secondary measures included the failure of kidneys to recover, the necessity for new renal replacement therapy (RRT), the occurrence of Major Adverse Kidney Events at 30 days (MAKE 30), and the duration of ICU stays.
To account for potential biases in treatment selection, researchers employed propensity score weighting, a statistical method used to balance patient characteristics between those who received aminoglycosides and those who did not.
Key Findings: Survival Rates and Renal Outcomes
The study encompassed 580 patients, with a median age of 69. More than half, 53.6%, were male. A significant portion, 57.8%, presented with septic shock, and 79.2% had AKI upon admission. Nearly all patients, 99.8%, received a beta-lactam antibiotic, with 444 receiving it in combination with an aminoglycoside and 136 receiving the beta-lactam alone.
The overall 30-day mortality rate was 10.5%.After statistical adjustment, the mortality rate for patients treated with aminoglycosides was 7.7%,compared to 12.1% for those who did not receive the drug. However, this difference was not statistically significant (adjusted hazard ratio [aHR] = 0.65 [0.35; 1.23] p = 0.19).
Researchers also found no significant differences between the two groups regarding kidney recovery (aHR = 0.88 [0.49; 1.58] p = 0.67),the need for RRT (aHR = 1.01 [0.54; 1.88] p = 0.97), MAKE 30 (aHR = 0.94 [0.60; 1.50] p = 0.81), or ICU length of stay (aHR = 1.07 [0.87; 1.31] p = 0.53).
Conclusions: Aminoglycosides and Urosepsis Treatment
The study suggests that the addition of aminoglycosides to empirical antibiotic therapy does not significantly improve 30-day survival rates for urosepsis patients in the ICU. Importantly, the research also indicated that aminoglycoside use was not associated with worsened kidney outcomes.
Keywords
Acute kidney injury, aminoglycosides, Mortality, Septic shock, Urinary tract infections.
Aminoglycosides and Urosepsis Treatment: A Study of ICU Patients
What is Urosepsis?
Urosepsis is a severe infection that originates in the urinary tract. It can lead to septic shock, a life-threatening condition requiring immediate treatment in the ICU.
Why are aminoglycosides Used in Urosepsis Treatment?
Current guidelines often reccommend a combination of a beta-lactam antibiotic and an aminoglycoside to treat urosepsis. Aminoglycosides, as a class of antibiotics, are known for their effectiveness against certain bacteria. However, a potential risk involves kidney damage (nephrotoxicity).
Study Overview: Aminoglycosides and 30-day survival Rates in Urosepsis
A retrospective study, conducted by the Assistance Publique-Hôpitaux de Paris (APHP) network, evaluated the impact of aminoglycosides on adult ICU patients with urosepsis or septic shock. The study ran from January 2015 to May 2022, aiming to assess 30-day survival and kidney-related outcomes.
What Were the Study’s Main Findings?
The study analyzed data from 580 patients. The study revealed the following key results:
- 30-Day Mortality: The overall mortality rate was 10.5%. After statistical adjustment, the mortality rate was 7.7% for patients treated with aminoglycosides compared to 12.1% for those who did not receive the drug, but this difference was not statistically notable.
- Kidney Outcomes: The study found no significant differences between aminoglycoside use and outcomes such as kidney recovery, the need for renal replacement therapy (RRT), Major Adverse Kidney Events at 30 days (MAKE 30), and ICU length of stay.
Did aminoglycosides Improve Survival in Urosepsis Patients?
according to the study, the addition of aminoglycosides to empirical antibiotic therapy did not significantly improve 30-day survival rates for urosepsis patients in the ICU. It is crucial to note that this result is drawn directly from the provided document.
Were There Any Negative Kidney Effects Associated With Aminoglycosides?
The research indicated that aminoglycoside use was NOT associated with worsened kidney outcomes. This is an important finding given the known potential for aminoglycosides to cause kidney damage.
Key Outcomes Compared Between Aminoglycoside and Non-Aminoglycoside Groups
The study’s main findings can be summarized in the following table:
| Outcome | Aminoglycoside Group | Non-Aminoglycoside Group | Adjusted Hazard Ratio (aHR) [95% CI] & p-value |
|---|---|---|---|
| 30-Day Mortality | 7.7% | 12.1% | 0.65 [0.35; 1.23] p = 0.19 |
| Kidney Recovery | Not specified | Not specified | 0.88 [0.49; 1.58] p = 0.67 |
| Need for RRT | Not specified | Not specified | 1.01 [0.54; 1.88] p = 0.97 |
| MAKE 30 | Not specified | not specified | 0.94 [0.60; 1.50] p = 0.81 |
| ICU Length of Stay | Not specified | Not specified | 1.07 [0.87; 1.31] p = 0.53 |
Study Conclusion
the study suggests that while aminoglycosides might not improve 30-day survival rates, they also did not worsen kidney outcomes in urosepsis patients within the ICU. These results highlight that in the specific context of the study it is not expected that the routine addition of aminoglycosides is expected to yield significant benefit.
Keywords
Acute kidney injury, aminoglycosides, Mortality, septic shock, urinary tract infections.